---
document_datetime: 2025-12-02 05:46:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ferriprox.html
document_name: ferriprox.html
version: success
processing_time: 0.1297921
conversion_datetime: 2025-12-24 14:47:29.065438
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ferriprox

[RSS](/en/individual-human-medicine.xml/66027)

##### Authorised

This medicine is authorised for use in the European Union

deferiprone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ferriprox](#news-on)
- [Related information](#related-information-589)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78653)
- [More information on Ferriprox](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ferriprox is an 'iron chelator' (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body.

Ferriprox is used:

- on its own, when standard iron chelator treatment cannot be used or does not work well enough;
- in combination with another iron chelator, when treatment with one iron chelator on its own does not work or when iron levels need to be rapidly or intensively corrected to prevent or treat life-threatening conditions (mainly affecting the heart).

Ferriprox contains the active substance deferiprone.

Expand section

Collapse section

## How is Ferriprox used?

Ferriprox can only be obtained with a prescription and treatment should be started and continued by a doctor who has experience in the treatment of thalassaemia. It is available as tablets (500 and 1,000 mg) and as an oral solution (100 mg/ml).

The usual dose of Ferriprox is 25 mg per kilogram body weight three times a day. The doctor may adjust the dose of Ferriprox according to how well the patient's iron levels are being controlled, which should be measured every 2 to 3 months with blood tests. The total dose for the whole day should be less than 100 mg per kilogram body weight. The doctor may interrupt treatment if iron levels get too low.

For more information about using Ferriprox, see the package leaflet or contact your doctor or pharmacist.

## How does Ferriprox work?

Patients with thalassaemia major need frequent blood transfusions. Transfused red cells bring iron into the body. With repeated transfusions, the iron builds up because the body does not have a natural way of removing excess iron. Over time, the excess iron can damage important organs such as the heart and liver. The active substance in Ferriprox, deferiprone, is an iron chelator. It attaches to iron in the body to form a compound that can be removed from the body, mainly in the urine, and to a lesser extent in the stools. Removing iron in this way helps to correct the iron overload and prevent damage from excess iron.

## What benefits of Ferriprox have been shown in studies?

Ferriprox was studied in 247 patients with thalassaemia major, aged over 6 years. The main measure of effectiveness was the change in the levels of ferritin in the blood. The blood ferritin level indicates how much iron is being stored in the body.

The main study involving 71 patients compared Ferriprox with deferoxamine, another iron chelator, over 2 years. Deferoxamine was given by injection under the skin overnight. The average blood ferritin levels were similar in the two treatment groups. However, the average iron concentration in the liver of Ferriprox-treated patients seemed to increase more than in deferoxamine-treated patients.

In another study involving 60 patients treated over 12 months, a combination of Ferriprox and deferoxamine (Ferriprox for 5 days plus deferoxamine for 2 days each week) was compared with deferoxamine on its own. Blood ferritin levels were reduced to the same extent in patients treated with the combination as with deferoxamine on its own. There were too few patients in the study to prove whether such a schedule is as effective as deferoxamine on its own.

In addition, published studies on Ferriprox together with deferoxamine reported greater reductions in blood ferritin levels when both medicines were used in combination compared with using either medicine on its own. In a published study, Ferriprox together with deferoxamine also led to greater decreases in iron in the heart compared with patients taking deferoxamine alone.

## What are the risks associated with Ferriprox?

The most common side effects with Ferriprox (which may affect more than 1 in 10 people) are red-brown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting. Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections).

Ferriprox must not be used in people who have had neutropenia repeatedly or agranulocytosis. Ferriprox must also not be used with medicines that might cause neutropenia or agranulocytosis. When taking Ferriprox, the patient's neutrophil count should be checked regularly (every week in the first year then less frequently). If the patient gets an infection, treatment with Ferriprox should be temporarily stopped and the neutrophil count checked more often. Patients should tell their doctor immediately if they have symptoms of an infection, such as fever, sore throat and flu-like symptoms.

Ferriprox must not be used in women who are pregnant or breastfeeding.

For the full list of restrictions and side effects of Ferriprox, see the package leaflet.

## Why is Ferriprox authorised in the EU?

The European Medicines Agency decided that Ferriprox's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ferriprox?

The company that markets Ferriprox must supply a reminder card for patients or their carers about the importance of regular tests for neutrophil counts, the need to watch out for symptoms of infection and for women to avoid becoming pregnant during treatment with Ferriprox.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ferriprox have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ferriprox are continuously monitored. Side effects reported with Ferriprox are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ferriprox

Ferriprox received a marketing authorisation valid throughout the EU on 25 August 1999.

Ferriprox : EPAR - Medicine overview

Reference Number: EMA/473109/2019

English (EN) (107.27 KB - PDF)

**First published:** 28/10/2009

**Last updated:** 28/10/2019

[View](/en/documents/overview/ferriprox-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-707)

български (BG) (147.89 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/bg/documents/overview/ferriprox-epar-medicine-overview_bg.pdf)

español (ES) (107.91 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/es/documents/overview/ferriprox-epar-medicine-overview_es.pdf)

čeština (CS) (131.34 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/cs/documents/overview/ferriprox-epar-medicine-overview_cs.pdf)

dansk (DA) (105.52 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/da/documents/overview/ferriprox-epar-medicine-overview_da.pdf)

Deutsch (DE) (108.39 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/de/documents/overview/ferriprox-epar-medicine-overview_de.pdf)

eesti keel (ET) (104.81 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/et/documents/overview/ferriprox-epar-medicine-overview_et.pdf)

ελληνικά (EL) (154.99 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/el/documents/overview/ferriprox-epar-medicine-overview_el.pdf)

français (FR) (108.28 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/fr/documents/overview/ferriprox-epar-medicine-overview_fr.pdf)

hrvatski (HR) (127.63 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/hr/documents/overview/ferriprox-epar-medicine-overview_hr.pdf)

italiano (IT) (106.68 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/it/documents/overview/ferriprox-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (129.87 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/lv/documents/overview/ferriprox-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (132.49 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/lt/documents/overview/ferriprox-epar-medicine-overview_lt.pdf)

magyar (HU) (126.05 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/hu/documents/overview/ferriprox-epar-medicine-overview_hu.pdf)

Malti (MT) (146.43 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/mt/documents/overview/ferriprox-epar-medicine-overview_mt.pdf)

Nederlands (NL) (105.91 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/nl/documents/overview/ferriprox-epar-medicine-overview_nl.pdf)

polski (PL) (132.07 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/pl/documents/overview/ferriprox-epar-medicine-overview_pl.pdf)

português (PT) (107.93 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/pt/documents/overview/ferriprox-epar-medicine-overview_pt.pdf)

română (RO) (137.17 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/ro/documents/overview/ferriprox-epar-medicine-overview_ro.pdf)

slovenčina (SK) (131.46 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/sk/documents/overview/ferriprox-epar-medicine-overview_sk.pdf)

slovenščina (SL) (127.27 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/sl/documents/overview/ferriprox-epar-medicine-overview_sl.pdf)

Suomi (FI) (105.82 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/fi/documents/overview/ferriprox-epar-medicine-overview_fi.pdf)

svenska (SV) (106.44 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

28/10/2019

[View](/sv/documents/overview/ferriprox-epar-medicine-overview_sv.pdf)

Ferriprox : EPAR - Risk management plan

English (EN) (732.51 KB - PDF)

**First published:** 26/03/2019

**Last updated:** 27/02/2023

[View](/en/documents/rmp/ferriprox-epar-risk-management-plan_en.pdf)

## Product information

Ferriprox : EPAR - Product Information

English (EN) (551.83 KB - PDF)

**First published:** 28/10/2009

**Last updated:** 13/08/2025

[View](/en/documents/product-information/ferriprox-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-825)

български (BG) (703.32 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/bg/documents/product-information/ferriprox-epar-product-information_bg.pdf)

español (ES) (522.71 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/es/documents/product-information/ferriprox-epar-product-information_es.pdf)

čeština (CS) (635.62 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/cs/documents/product-information/ferriprox-epar-product-information_cs.pdf)

dansk (DA) (530.66 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/da/documents/product-information/ferriprox-epar-product-information_da.pdf)

Deutsch (DE) (561.84 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/de/documents/product-information/ferriprox-epar-product-information_de.pdf)

eesti keel (ET) (522.69 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/et/documents/product-information/ferriprox-epar-product-information_et.pdf)

ελληνικά (EL) (643.13 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/el/documents/product-information/ferriprox-epar-product-information_el.pdf)

français (FR) (546 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/fr/documents/product-information/ferriprox-epar-product-information_fr.pdf)

hrvatski (HR) (565.57 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/hr/documents/product-information/ferriprox-epar-product-information_hr.pdf)

íslenska (IS) (517.83 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/is/documents/product-information/ferriprox-epar-product-information_is.pdf)

italiano (IT) (554.91 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/it/documents/product-information/ferriprox-epar-product-information_it.pdf)

latviešu valoda (LV) (613.9 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/lv/documents/product-information/ferriprox-epar-product-information_lv.pdf)

lietuvių kalba (LT) (622.34 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/lt/documents/product-information/ferriprox-epar-product-information_lt.pdf)

magyar (HU) (683.38 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/hu/documents/product-information/ferriprox-epar-product-information_hu.pdf)

Malti (MT) (718.06 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/mt/documents/product-information/ferriprox-epar-product-information_mt.pdf)

Nederlands (NL) (541.96 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/nl/documents/product-information/ferriprox-epar-product-information_nl.pdf)

norsk (NO) (582.78 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/no/documents/product-information/ferriprox-epar-product-information_no.pdf)

polski (PL) (619.66 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/pl/documents/product-information/ferriprox-epar-product-information_pl.pdf)

português (PT) (546.04 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/pt/documents/product-information/ferriprox-epar-product-information_pt.pdf)

română (RO) (618.23 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/ro/documents/product-information/ferriprox-epar-product-information_ro.pdf)

slovenčina (SK) (611.92 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/sk/documents/product-information/ferriprox-epar-product-information_sk.pdf)

slovenščina (SL) (584.34 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/sl/documents/product-information/ferriprox-epar-product-information_sl.pdf)

Suomi (FI) (529.47 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/fi/documents/product-information/ferriprox-epar-product-information_fi.pdf)

svenska (SV) (518.91 KB - PDF)

**First published:**

28/10/2009

**Last updated:**

13/08/2025

[View](/sv/documents/product-information/ferriprox-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000291625 12/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ferriprox : EPAR - All Authorised presentations

English (EN) (15.03 KB - PDF)

**First published:** 27/11/2007

**Last updated:** 07/09/2010

[View](/en/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-995)

български (BG) (88.79 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/bg/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.04 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/es/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_es.pdf)

čeština (CS) (83.95 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/cs/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.66 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/da/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.9 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/de/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.08 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/et/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (85.61 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/el/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_el.pdf)

français (FR) (18.43 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/fr/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.52 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/hr/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.42 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/is/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.47 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/it/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (87.97 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/lv/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (86.03 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/lt/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (88.07 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/hu/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (85.37 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/mt/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.29 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/nl/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.56 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/no/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_no.pdf)

polski (PL) (89.95 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/pl/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.87 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/pt/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_pt.pdf)

română (RO) (84.99 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/ro/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (86.83 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/sk/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.29 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/sl/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.53 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/fi/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.7 KB - PDF)

**First published:**

27/11/2007

**Last updated:**

07/09/2010

[View](/sv/documents/all-authorised-presentations/ferriprox-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ferriprox Active substance Deferiprone International non-proprietary name (INN) or common name deferiprone Therapeutic area (MeSH)

- beta-Thalassemia
- Iron Overload

Anatomical therapeutic chemical (ATC) code V03AC02

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.

Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

## Authorisation details

EMA product number EMEA/H/C/000236 Marketing authorisation holder

Chiesi Farmaceutici S.p.A.

Via Palermo 26/A

Marketing authorisation issued 25/08/1999 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ferriprox : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (535.4 KB - PDF)

**First published:** 13/08/2025

[View](/en/documents/procedural-steps-after/ferriprox-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ferriprox : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (346.58 KB - PDF)

**First published:** 28/10/2009

**Last updated:** 13/08/2025

[View](/en/documents/procedural-steps-after/ferriprox-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ferriprox-H-C-PSUSA-00000940-201608 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/394748/2017

English (EN) (69.65 KB - PDF)

**First published:** 21/06/2017

**Last updated:** 21/06/2017

[View](/en/documents/scientific-conclusion/ferriprox-h-c-psusa-00000940-201608-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Ferriprox-H-C-236-II-0103 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/ 591403/2015

English (EN) (817.78 KB - PDF)

**First published:** 14/07/2016

**Last updated:** 14/07/2016

[View](/en/documents/variation-report/ferriprox-h-c-236-ii-0103-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ferriprox

Adopted

Reference Number: EMA/CHMP/284564/2016

English (EN) (61.46 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 29/04/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ferriprox_en.pdf)

Ferriprox : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (104.13 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/steps-after-cutoff/ferriprox-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Ferriprox : EPAR - Procedural steps taken before authorisation

English (EN) (96.5 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/procedural-steps/ferriprox-epar-procedural-steps-taken-authorisation_en.pdf)

Ferriprox : EPAR - Scientific Discussion

English (EN) (246.55 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/scientific-discussion/ferriprox-epar-scientific-discussion_en.pdf)

#### News on Ferriprox

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 April 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-april-2016) 29/04/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2016) 26/02/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC000236II0103) (variation II/0103)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Ferriprox : EPAR - Product information - tracked changes

English (EN) (156.47 KB - DOCX)

**First published:** 13/08/2025

[View](/en/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-957)

български (BG) (157.32 KB - DOCX)

**First published:**

13/08/2025

[View](/bg/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_bg.docx)

español (ES) (141.69 KB - DOCX)

**First published:**

13/08/2025

[View](/es/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_es.docx)

čeština (CS) (142.06 KB - DOCX)

**First published:**

13/08/2025

[View](/cs/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (139.52 KB - DOCX)

**First published:**

13/08/2025

[View](/da/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (164.32 KB - DOCX)

**First published:**

13/08/2025

[View](/de/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (163.72 KB - DOCX)

**First published:**

13/08/2025

[View](/et/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (157.87 KB - DOCX)

**First published:**

13/08/2025

[View](/el/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_el.docx)

français (FR) (146.66 KB - DOCX)

**First published:**

13/08/2025

[View](/fr/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (136.06 KB - DOCX)

**First published:**

13/08/2025

[View](/hr/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (140.61 KB - DOCX)

**First published:**

13/08/2025

[View](/is/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_is.docx)

italiano (IT) (146.64 KB - DOCX)

**First published:**

13/08/2025

[View](/it/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (171.94 KB - DOCX)

**First published:**

13/08/2025

[View](/lv/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (166.21 KB - DOCX)

**First published:**

13/08/2025

[View](/lt/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (173.43 KB - DOCX)

**First published:**

13/08/2025

[View](/hu/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (145.09 KB - DOCX)

**First published:**

13/08/2025

[View](/mt/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (158.16 KB - DOCX)

**First published:**

13/08/2025

[View](/nl/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (153.69 KB - DOCX)

**First published:**

13/08/2025

[View](/no/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_no.docx)

polski (PL) (148.41 KB - DOCX)

**First published:**

13/08/2025

[View](/pl/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_pl.docx)

português (PT) (163.04 KB - DOCX)

**First published:**

13/08/2025

[View](/pt/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_pt.docx)

română (RO) (139.04 KB - DOCX)

**First published:**

13/08/2025

[View](/ro/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (165.13 KB - DOCX)

**First published:**

13/08/2025

[View](/sk/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (143.2 KB - DOCX)

**First published:**

13/08/2025

[View](/sl/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (155.77 KB - DOCX)

**First published:**

13/08/2025

[View](/fi/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (139.5 KB - DOCX)

**First published:**

13/08/2025

[View](/sv/documents/product-information-tracked-changes/ferriprox-epar-product-information-tracked-changes_sv.docx)

#### More information on Ferriprox

- [Long-term observational safety study to evaluate the nature and incidence of adverse effects of deferiprone treatment in patients with beta-thalassaemia major aged from 1 month to less than 18 years. (DEEP-3) - post-authorisation study](https://catalogues.ema.europa.eu/study/12034)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/08/2025

## Share this page

[Back to top](#main-content)